Literature DB >> 19107979

Seroepidemiology of EBV and interpretation of the "isolated VCA IgG" pattern.

Massimo De Paschale1, Carlo Agrappi, Maria Teresa Manco, Paola Mirri, Egidio Franco Viganò, Pierangelo Clerici.   

Abstract

The presence of VCA IgG in the absence of VCA IgM and EBNA-1 IgG antibodies makes classifying EBV infection more difficult as this serological picture can be seen in the case of past infection with EBNA-1 IgG loss or non-appearance, or acute infections with the early disappearance or delayed onset of VCA IgM. The aim of this study was to assess the prevalence of this pattern in 2,422 outpatients with suspected EBV infection examined in 2005-2006, and to interpret its significance by means of immunoblotting. One hundred and seventy-seven (7.3%) of the patients were VCA IgG-positive, VCA IgM-negative and EBNA-1 IgG-negative, 15 of whom (8.5%) presented with heterophile antibodies. Analysis by age class showed that the prevalence of isolated VCA IgG ranged from 4.5% in the subjects aged 1-10 years to 9% in those aged >60 years. Immunoblotting allowed 18.9% of the cases to be classified as acute and 81.1% as past infections, the latter being observed in about 37% of the patients aged less than 10 years and in 100% of those aged >30 years. Therefore, in our case series, the presence of isolated VCA IgG was associated usually with past infection, particularly among adults. In children aged less than 10 years, it was associated mainly with acute infection but as past infection may be present in about one-third of such children, this possibility should not be overlooked. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19107979     DOI: 10.1002/jmv.21373

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  14 in total

1.  Genetic factors influence serological measures of common infections.

Authors:  Rohina Rubicz; Charles T Leach; Ellen Kraig; Nikhil V Dhurandhar; Ravindranath Duggirala; John Blangero; Robert Yolken; Harald H H Göring
Journal:  Hum Hered       Date:  2011-10-11       Impact factor: 0.444

2.  Performance of two commercially available automated immunoassays for the determination of Epstein-Barr virus serological status.

Authors:  J Lupo; R Germi; T Semenova; M Buisson; J M Seigneurin; P Morand
Journal:  Clin Vaccine Immunol       Date:  2012-04-25

Review 3.  Serological diagnosis of Epstein-Barr virus infection: Problems and solutions.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2012-02-12

4.  Evaluation of the Architect Epstein-Barr Virus (EBV) viral capsid antigen (VCA) IgG, VCA IgM, and EBV nuclear antigen 1 IgG chemiluminescent immunoassays for detection of EBV antibodies and categorization of EBV infection status using immunofluorescence assays as the reference method.

Authors:  Isabel Corrales; Estela Giménez; David Navarro
Journal:  Clin Vaccine Immunol       Date:  2014-03-12

5.  Evaluation of four commercial systems for the diagnosis of Epstein-Barr virus primary infections.

Authors:  Fernando de Ory; María Eulalia Guisasola; Juan Carlos Sanz; Isabel García-Bermejo
Journal:  Clin Vaccine Immunol       Date:  2010-12-29

6.  Facial nerve palsy secondary to Epstein-Barr virus infection of the middle ear in pediatric population may be more common than we think.

Authors:  Katarina Vogelnik; Aleš Matos
Journal:  Wien Klin Wochenschr       Date:  2017-09-18       Impact factor: 1.704

7.  Search for Anti-EA(D) Antibodies in Subjects with an "Isolated VCA IgG" Pattern.

Authors:  Massimo De Paschale; Debora Cagnin; Teresa Cerulli; Maria Teresa Manco; Carlo Agrappi; Paola Mirri; Arianna Gatti; Cristina Rescaldani; Pierangelo Clerici
Journal:  Int J Microbiol       Date:  2010-06-20

8.  Reliability of the Siemens Enzygnost and Novagnost Epstein-Barr virus assays for routine laboratory diagnosis: agreement with clinical diagnosis and comparison with the Merifluor Epstein-Barr virus immunofluorescence assay.

Authors:  Christina Kreuzer; Klaus Udo Nabeck; H Roma Levy; Elisabeth Daghofer
Journal:  BMC Infect Dis       Date:  2013-06-03       Impact factor: 3.090

9.  A genome-wide integrative genomic study localizes genetic factors influencing antibodies against Epstein-Barr virus nuclear antigen 1 (EBNA-1).

Authors:  Rohina Rubicz; Robert Yolken; Eugene Drigalenko; Melanie A Carless; Thomas D Dyer; Lara Bauman; Phillip E Melton; Jack W Kent; John B Harley; Joanne E Curran; Matthew P Johnson; Shelley A Cole; Laura Almasy; Eric K Moses; Nikhil V Dhurandhar; Ellen Kraig; John Blangero; Charles T Leach; Harald H H Göring
Journal:  PLoS Genet       Date:  2013-01-10       Impact factor: 5.917

10.  The impact of serological features in Chinese children with primary or past Epstein-Barr virus infections.

Authors:  Yuan Huang; Cong Wei; Kun Zheng; Dongchi Zhao
Journal:  Virol J       Date:  2013-02-13       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.